These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 14979210)

  • 21. Participation of adrenomedullin and its relation with vascular endothelial growth factor in androgen regulation of prostatic blood flow in vivo.
    Shibata Y; Kashiwagi B; Arai S; Magari T; Suzuki K; Honma S
    Urology; 2006 Nov; 68(5):1127-31. PubMed ID: 17113911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis.
    Liu D; Evans I; Britton G; Zachary I
    Oncogene; 2008 May; 27(21):2989-98. PubMed ID: 18059339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
    Zeng Y; Opeskin K; Goad J; Williams ED
    Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
    Tang J; Wang Z; Li X; Li J; Shi H
    Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(2):83-93. PubMed ID: 18437586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer.
    Hrouda D; Nicol DL; Gardiner RA
    Urol Res; 2003 Feb; 30(6):347-55. PubMed ID: 12599013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion.
    Keledjian K; Garrison JB; Kyprianou N
    J Cell Biochem; 2005 Feb; 94(2):374-88. PubMed ID: 15526277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression.
    Liu Z; Kobayashi K; van Dinther M; van Heiningen SH; Valdimarsdottir G; van Laar T; Scharpfenecker M; Löwik CW; Goumans MJ; Ten Dijke P; Pardali E
    J Cell Sci; 2009 Sep; 122(Pt 18):3294-302. PubMed ID: 19706683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.
    Takahashi H; Shibuya M
    Clin Sci (Lond); 2005 Sep; 109(3):227-41. PubMed ID: 16104843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue.
    Lekas A; Lazaris AC; Deliveliotis C; Chrisofos M; Zoubouli C; Lapas D; Papathomas T; Fokitis I; Nakopoulou L
    Anticancer Res; 2006; 26(4B):2989-93. PubMed ID: 16886625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xanthine oxidase interaction with vascular endothelial growth factor in human endothelial cell angiogenesis.
    Kou B; Ni J; Vatish M; Singer DR
    Microcirculation; 2008 Apr; 15(3):251-67. PubMed ID: 18386220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells.
    Yano A; Fujii Y; Iwai A; Kageyama Y; Kihara K
    Clin Cancer Res; 2006 May; 12(10):3003-9. PubMed ID: 16707595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benign prostatic hyperplasia due to venous drainage malfunction in the male reproductive system: a price of erect posture in humans.
    Schill WB; Ben-Shlomo I
    Andrologia; 2008 Oct; 40(5):272. PubMed ID: 18811915
    [No Abstract]   [Full Text] [Related]  

  • 38. What type of VEGF do you need?
    Kennedy CR
    J Am Soc Nephrol; 2010 Sep; 21(9):1410-2. PubMed ID: 20705715
    [No Abstract]   [Full Text] [Related]  

  • 39. VEGF tips its hand in angiogenesis.
    Short B
    J Cell Biol; 2015 May; 209(4):474. PubMed ID: 26008740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Testicular changes in prostate carcinoma; case report & histochemical findings].
    LANDI E
    Riv Anat Patol Oncol; 1958 May; 14(2):284-94. PubMed ID: 13658851
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.